Item type |
itemtype_ver1(1) |
公開日 |
2021-12-03 |
タイトル |
|
|
タイトル |
Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy |
|
言語 |
en |
著者 |
Oie, Yumi
Itoh, Yoshiyuki
Kawamura, Mariko
Takase, Yuuki
Murao, Takayuki
Ishihara, Shunichi
Nomoto, Yoshihito
Hirasawa, Naoki
Asano, Akiko
Yamakawa, Kouji
Ito, Junji
Kinoshita, Fumie
Naganawa, Shinji
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利 |
|
|
言語 |
en |
|
権利情報Resource |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
T1 glottic cancer |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hypofractionated radiotherapy |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
2.25 Gy |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
ulcerative tumor type |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The Tokai Study Group for Therapeutic Radiology and Oncology (TOSTRO) started managing T1 glottic cancer using 2.25 Gy/fraction radiotherapy in 2011. The aim was to evaluate the local control (LC) rate and toxicity with 2.25-Gy radiotherapy in clinical practice and identify prognostic factors.The eligibility criteria were T1 glottic squamous cell carcinoma patients with age ≥20 years, treated with 2.25 Gy/fraction without chemotherapy between 2011 and 2017. LC rates were evaluated based on age, performance status, sex, T-category, tumor type (ulcerative or non-ulcerative), presence of anterior commissure invasion, tumor size, X-ray beam energy, and overall treatment time. Acute and late adverse events were evaluated using CTCAE version 4.0. A total of 202 patients were enrolled. The median follow-up period was 34.2 months. The 2- and 4-year LC rates were 93.8% and 93.1%, respectively. There was a significant difference in the LC rate between non-ulcerative type and ulcerative type (95.2% vs. 74.1% at 2 years, 94.4% vs. 74.1% at 4 years; p = 0.01). On univariate analysis, only tumor type was significantly correlated with a poor LC rate (hazard ratio 4.3; 95% confidence interval 1.2–15.4; p = 0.03). Acute grade 3 adverse events occurred in 17 patients. However, no late adverse events of grade 3 or higher have occurred to date. T1 glottic cancer treatment outcomes using hypofractionated radiotherapy with 2.25 Gy/fraction in clinical practice were comparable to previously reported results. However, ulcerative type tumor was associated with a poor LC rate. |
|
言語 |
en |
出版者 |
|
|
出版者 |
Nagoya University Graduate School of Medicine, School of Medicine |
|
言語 |
en |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
ID登録 |
|
|
ID登録 |
10.18999/nagjms.83.4.811 |
|
ID登録タイプ |
JaLC |
関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/834.html |
収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0027-7622 |
収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2186-3326 |
書誌情報 |
en : Nagoya Journal of Medical Science
巻 83,
号 4,
p. 811-825,
発行日 2021-11
|